Fulcrum Therapeutics (FULC) Operating Expenses (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Operating Expenses data on file, last reported at $22.2 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $22.2 million, up 8.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $86.6 million (down 6.4% YoY), and the FY2025 annual result was $84.8 million, down 16.81% from the prior year.
• Operating Expenses slipped to $22.2 million in Q1 2026 per FULC's latest filing, from $22.7 million in the prior quarter.
• Over five years, Operating Expenses peaked at $36.1 million in Q2 2022 and troughed at $19.4 million in Q4 2024.
• A 5-year average of $26.0 million and a median of $27.5 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2024: Operating Expenses surged 50.09% in 2022, then slumped 32.69% in 2024.
• A 5-year view of Operating Expenses shows it stood at $28.7 million in 2022, then increased by 0.72% to $28.9 million in 2023, then slumped by 32.69% to $19.4 million in 2024, then rose by 16.8% to $22.7 million in 2025, then slipped by 2.23% to $22.2 million in 2026.
• Business Quant data shows FULC's Operating Expenses at $22.2 million in Q1 2026, $22.7 million in Q4 2025, and $21.9 million in Q3 2025.